Detectnet (64Cu-Dotatate) / RadioMedix, Curium - LARVOL DELTA

Study of Dotatate Imaging in Breast Cancer (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Hoag Memorial Hospital Presbyterian | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Jul 2023 ➔ Jul 2024

Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Study of Dotatate Imaging in Breast Cancer (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Hoag Memorial Hospital Presbyterian | Phase classification: P2 ➔ P1

Metastases • Phase classification • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms. (PubMed, J Nucl Med) - " PET improved visual similarity with PET compared with PET, and PET and PET had similar Likert scale-defined image quality. However, lesion detection analysis performed by physicians showed high proportions of FP and FN lesions on PET, highlighting the need for clinical validation of AI algorithms."

Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Management of Ectopic ACTH Syndrome with Liver Metastases – A Case Series (AACE 2023) - "The cortisol did not suppress with 1-mg or 8-mg dexamethasone...A PET scan (64Cu-DOTATATE in patient A, F18-FDG in patient B, and 68Ga DOTATATE in patient C) revealed hepatic metastases in all patients. Patient A was started on levoketoconazole and metyrapone, underwent trans-arterial radio-embolization (TARE) of the liver metastases, after which levoketoconazole was stopped...While surgical excision of the primary tumor is curative, patients might present with symptomatic hypercortisolism and unknown primary tumor or metastatic disease. Utilizing steroidogenic inhibitors to alleviate hypercortisolism and using TAE/TARE for patients with liver metastases to reduce disease burden, when appropriate, will improve quality of life and preserve adrenal function as compared to bilateral adrenalectomy."

Clinical • Cardiovascular • Diabetes • Endocrine Cancer • Endocrine Disorders • Gastrointestinal Cancer • Hepatocellular Cancer • Hypertension • Infectious Disease • Neuroendocrine Tumor • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms (clinicaltrials.gov) - P2 | N=200 | Enrolling by invitation | Sponsor: Rigshospitalet, Denmark

FDG PET • New P2 trial • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

Gastro-Entero-Pancreatic Tumors: FDG Positron Emission Tomography/Computed Tomography. (PubMed, PET Clin) - "Moreover, with the advent of newer radiopharmaceuticals, such as 68 Ga-labeled and 64 Cu-labeled somatostatin analogs (eg, 68 Ga-DOTATOC, 68 Ga-DOTATATE, 68 Ga-DOTANOC, and 64Cu-DOTATATE) that bind to the somatostatin receptor (SSTR), molecular imaging plays an increasing and critical role in the diagnosis, staging, and treatment planning of these neoplasms. Dual-tracer imaging with 18F-FDG PET/CT and SSTR agents may play a significant role in treatment planning and predicting patient outcomes in the setting of high-grade or poorly differentiated neuroendocrine tumors."

Journal • Review • Endocrine Cancer • Gastrointestinal Cancer • Hepatology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

64Cu-DOTATATE Uptake in a Pulmonary Hamartoma. (PubMed, Clin Nucl Med) - "We report an unexpected case of pulmonary hamartoma demonstrating 64Cu-DOTATATE uptake in a 43-year-old woman with a slowly enlarging pulmonary nodule. Histopathological staining showed somatostatin receptor 2 expression on vascular endothelial cells and a proportion of cartilage and smooth muscle cells within the hamartoma."

Journal • Carcinoid Tumor • SSTR • SSTR2

Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of Dotatate PET Scans (NANETS 2022) - "RESULTS A total of 22 patients were identified with metastatic lung NETs (3 typical, 19 atypical) who underwent either 68Ga or 64Cu Dotatate PET imaging...CONCLUSIONS The majority of metastatic lung NETs are either SSTR negative or express heterogenous patterns of SSTR expression and are thus suboptimal candidates for SSTR targeted therapy, particularly with PRRT. SSTR imaging in lung NETs should be evaluated carefully for uniformity of expression."

Carcinoid Tumor • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Targeted alpha-emitter therapy with 212Pb-DOTAMTATE in neuroendocrine tumor subjects who progressed following prior 177Lu/90Y-PRRT. (ASCO 2022) - P1 | "Response to treatment was measured per RECIST 1.1 criteria and by 68Ga/64Cu-DOTATATE PET/CT. This is the first clinical trial of 212Pb-targeted alpha-emitter therapy in subjects with NETs who progressed following prior PRRT. The use of 212Pb-DOTAMTATE in the recurrent setting is highly effective with manageable toxicity and warrants further investigation."

Clinical • Alopecia • Anemia • Asthma • Endocrine Cancer • Fatigue • Gastrointestinal Disorder • Hematological Disorders • Immunology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Septic Shock • Solid Tumor • SSTR

Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review. (PubMed, Pharmaceutics) - "We now have highly sensitive and specific diagnostic modalities like gallium 68 DOTATATE and copper 64 DOTATATE scans to screen for SSTR-2 and then target it therapeutically with lutetium 177 DOTATATE. A thorough understanding of SSTR expression in other tumors will open the channels for exploring potential SSTR targeting."

Journal • Review • Oncology • SSTR • SSTR2

64Cu-DOTATATE PET-CT-skanning and Infective Endocarditis. (clinicaltrials.gov) - P=N/A | N=65 | Recruiting | Sponsor: Emil Loldrup Fosbol

New trial • Cardiovascular

Choice is good at times: the emergence of [Cu]Cu-DOTATATE based somatostatin receptor imaging in the era of [Ga]Ga-DOTATATE. (PubMed, J Nucl Med) - No abstract available

Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Reduction of 64Cu-DOTATATE activity dose for somatostatin receptor PET imaging of patients with neuroendocrine neoplasms (ENETS 2022) - "The activity dose of 64Cu-DOTATATE could be reduced by 25% to 142 MBq without affecting the diagnostic image quality or lesion detection confidence. Further reduction by 50% to 95 MBq was possible without loss of clinically relevant information."

Clinical • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Pheochromocytomas and paragangliomas. (PubMed, Curr Opin Pediatr) - "Genetics play an important role in pediatric PPGLs. Advances in somatostatin receptor-based technology have led to use of 68Ga-DOTATATE and 64Cu-DOTATATE as preferred imaging modalities. While surgery remains the mainstay for management of PPGLs, PRRT is emerging as a treatment option for PPGLs."

Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Pediatrics • Solid Tumor • SSTR

2020 FDA TIDES (Peptides and Oligonucleotides) Harvest. (PubMed, Pharmaceuticals (Basel)) - "The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Initial Experience with Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET. (PubMed, Diagnostics (Basel)) - "All 44 lesions detected on the analog PET with corresponding structural correlates on the CT were also found on the digital PET performed 137 (107-176) days later. Our initial findings suggest that digital Cu-DOTATATE PET can successfully be performed in patients with NENs using an image acquisition time of only 1/3 of what is used for an analog Cu-DOTATATE PET."

Clinical • Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

Semi-automatic tumor delineation for evaluation of Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume. (PubMed, J Nucl Med) - "Assessment of lowest, rather than highest lesion uptake greatly increases prognostication by Cu-DOTATATE PET/CT. Combing lesion uptake and total tumor volume, we derived a novel prognostic classification of patients with NEN."

Clinical • Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First US Prospective, Reader-Blinded Clinical Trial. (PubMed, J Nucl Med) - "No AEs were related to Cu-DOTATATE, and no serious AEs were observed. Cu-DOTATATE PET/CT is a safe imaging technique that provides high-quality and accurate images at a dose of 148 MBq (4.0 mCi) for the detection of somatostatin-expressing NETs."

Clinical • Journal • Neuroendocrine Tumor • Oncology • Solid Tumor

Cu-DOTATATE Positron Emission Tomography (PET) of Borrelia Burgdorferi Infection: In Vivo Imaging of Macrophages in Experimental Model of Lyme Arthritis. (PubMed, Diagnostics (Basel)) - "In contrast, measurement of a systemic macrophage marker in plasma, CD163, did not allow to detect disease. We suggest that Cu-DOTATATE PET could become a valuable diagnostic tool for in situ detection of Bb infection-related inflammation."

Journal • Preclinical • Immunology • Inflammation • Inflammatory Arthritis • Lyme Disease • Rheumatology • CD163

[VIRTUAL] 64Cu-DOTATATE PET in Neuroendocrine Tumor Patients: What We Learned From the First 1,200 Patients (NANETS 2020) - "64Cu-DOTATATE is a safe and sensitive PET tracer for somatostatin receptor imaging. It has an excellent lesion detection rate and imaging can be performed from 1-3 h with same performance. In addition, 64Cu-DOTATATE is logistically convenient due to the long half-life and shelf-life of 24h."

Clinical • Neuroendocrine Tumor • Oncology • Solid Tumor

Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection. (PubMed, J Nucl Med) - "Throughout the 1-3 h p.i. imaging window, TTN (mean [95% confidence interval]) remained high in all key organs: Liver (1h p.i.: 12.6 [10.2; 14.9] , 3h p.i.: 11.0 [8.7; 13.4]), intestines (1h p.i.: 24.2 [14.9; 33.4], 3h p.i.: 28.2 [16.5; 40.0]), pancreas (1h p.i.: 42.4 [12.3; 72.5], 3h p.i.: 41.1 [8.7; 73.4]) and bone (1h p.i.: 103.0 [38.6; 167.4], 3h p.i.: 124.2 [57.1; 191.2]). Conclusion The imaging time window of Cu-DOTATATE PET/CT of patients with NEN can be expanded from 1h p.i. to 1-3 hours p.i. without significant differences in the number of lesions detected."

Clinical • Head-to-Head • Journal • Neuroendocrine Tumor • Oncology • Solid Tumor

64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast (ENETS 2020) - No abstract available

Clinical

64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms (ENETS 2020) - No abstract available

Clinical

Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms. (PubMed, J Nucl Med) - " In this first study to report the association of Cu-DOTATATE PET/CT and outcome in patients with NEN, tumor somatostatin receptor density visualized with Cu-DOTATATE PET/CT was prognostic for PFS but not OS. However, the accuracy of prediction of PFS at 24 months after Cu-DOTATATE PET/CT SRI was moderate limiting the value on an individual patient basis."

Clinical • Journal

Gamma emitters in pancreatic endocrine tumors imaging in the PET era: is there a clinical space for 99mTc-peptides? (PubMed, Curr Radiopharm) - "In our opinion, Tektroty"

Clinical • Journal